Lonafarnib Patent Expiration

Lonafarnib is Used for reducing the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS). It was first introduced by Sentynl Therapeutics Inc in its drug Zokinvy on Nov 20, 2020.


Lonafarnib Patents

Given below is the list of patents protecting Lonafarnib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zokinvy US7838531 Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis Jul 26, 2024

(Expired)

Sentynl Theraps Inc
Zokinvy US8828356 Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis Oct 17, 2024 Sentynl Theraps Inc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lonafarnib's patents.

Given below is the list recent legal activities going on the following patents of Lonafarnib.

Event Date Patent/Publication
Patent litigations
Requirement for information sent under 37 CFR 1.750 08 Jul, 2024 US7838531
Letter from FDA or Dept of Agriculture re PTE application 18 Jan, 2024 US7838531
transaction for FDA Determination of Regulatory Review Period 27 Dec, 2023 US7838531
Second letter to regulating agency to determine regulatory review period 10 Mar, 2023 US7838531
Letter from FDA or Dept of Agriculture re PTE application 09 Nov, 2022 US7838531
Payment of Maintenance Fee, 12th Year, Large Entity 03 Apr, 2022 US7838531
Initial letter Re: PTE Application to regulating agency 23 Feb, 2022 US7838531
Patent Term Extension Application under 35 USC 156 Filed 14 Jan, 2021 US7838531
Email Notification 11 Jan, 2021 US7838531
Change in Power of Attorney (May Include Associate POA) 11 Jan, 2021 US7838531



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳